CN116615430A - 杂环glp-1激动剂 - Google Patents
杂环glp-1激动剂 Download PDFInfo
- Publication number
- CN116615430A CN116615430A CN202180073815.0A CN202180073815A CN116615430A CN 116615430 A CN116615430 A CN 116615430A CN 202180073815 A CN202180073815 A CN 202180073815A CN 116615430 A CN116615430 A CN 116615430A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- independently selected
- compound according
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020113758 | 2020-09-07 | ||
| CNPCT/CN2020/113758 | 2020-09-07 | ||
| PCT/CN2021/116684 WO2022048665A1 (en) | 2020-09-07 | 2021-09-06 | Heterocyclic glp-1 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116615430A true CN116615430A (zh) | 2023-08-18 |
Family
ID=80491636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180073815.0A Pending CN116615430A (zh) | 2020-09-07 | 2021-09-06 | 杂环glp-1激动剂 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230322771A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4211133A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7821785B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN116615430A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022048665A1 (cg-RX-API-DMAC10.html) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119176808A (zh) * | 2024-11-25 | 2024-12-24 | 山东法恩新材料科技有限公司 | 一种glp-1激动剂及其制备方法和应用 |
| WO2025119206A1 (en) * | 2023-12-05 | 2025-06-12 | Fortvita Biologics Inc. | Glp-1 receptor targeting compounds and uses thereof |
| WO2026031819A1 (en) * | 2024-08-06 | 2026-02-12 | Insilico Medicine Ip Limited | Novel compounds as glp-1r agonists and uses thereof |
| WO2026086876A1 (zh) * | 2024-10-23 | 2026-04-30 | 郑州同源康医药有限公司 | 作为glp-1r激动剂的化合物 |
| WO2026145540A1 (zh) * | 2024-12-31 | 2026-07-09 | 正大天晴药业集团股份有限公司 | 含多稠环结构的化合物的结晶及其制备方法 |
| WO2026158226A1 (zh) * | 2025-01-21 | 2026-07-30 | 歌礼制药(中国)有限公司 | 一种glp-1r激动剂的注射剂及其制备方法 |
| WO2026158232A1 (zh) * | 2025-01-21 | 2026-07-30 | 歌礼制药(中国)有限公司 | 一种包含glp-1r激动剂的药物组合物及其制备方法 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| WO2022052958A1 (en) | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| JP2025510741A (ja) * | 2022-03-21 | 2025-04-15 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式glp-1アゴニスト |
| PE20250009A1 (es) * | 2022-05-11 | 2025-01-07 | Lilly Co Eli | Composiciones de comprimidos de glp1 |
| US20260217707A1 (en) * | 2023-01-17 | 2026-07-30 | Fochon Biosciences, Ltd. | Glp-1r agonists and uses thereof |
| KR20250168210A (ko) * | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| CN119630663B (zh) * | 2023-06-29 | 2025-10-21 | 韦恩生物科技有限公司 | 一种glp-1受体激动剂及其制备方法和用途 |
| TW202506108A (zh) * | 2023-06-30 | 2025-02-16 | 大陸商正大天晴藥業集團股份有限公司 | 含多稠環結構的化合物 |
| AU2024317579A1 (en) * | 2023-07-28 | 2026-02-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof |
| WO2025026436A1 (zh) * | 2023-08-02 | 2025-02-06 | 韦恩生物科技有限公司 | 一种含氮并环化合物及其制备方法和用途 |
| EP4771001A1 (en) * | 2023-08-31 | 2026-07-08 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025097835A1 (zh) * | 2023-11-10 | 2025-05-15 | 重庆医药工业研究院有限责任公司 | 一种glp-1r激动剂化合物及其应用 |
| KR20260118441A (ko) | 2023-11-21 | 2026-07-30 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용 |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2025209515A1 (zh) * | 2024-04-03 | 2025-10-09 | 广州市联瑞制药有限公司 | 一种glp-1受体激动剂及其制备方法和应用 |
| WO2025264023A1 (en) * | 2024-06-19 | 2025-12-26 | Chong Kun Dang Pharmaceutical Corp. | Glp-1 receptor agonist, and uses thereof |
| WO2026096330A1 (en) * | 2024-10-28 | 2026-05-07 | Merck Sharp & Dohme Llc | Glp-1 receptor agonists and methods of use |
| WO2026158353A1 (zh) * | 2025-01-23 | 2026-07-30 | 联邦生物科技(珠海横琴)有限公司 | 具有glp-1受体激动剂效应的杂环化合物及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927214B1 (en) * | 1999-01-15 | 2005-08-09 | Novo Nordisk A/S | Non-peptide GLP-1 agonists |
| CN109790161A (zh) * | 2016-09-26 | 2019-05-21 | 中外制药株式会社 | 具有glp-1受体激动剂作用的吡唑并吡啶衍生物 |
| JP2019099571A (ja) * | 2017-11-29 | 2019-06-24 | 中外製薬株式会社 | Glp−1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
-
2021
- 2021-09-06 US US18/044,196 patent/US20230322771A1/en active Pending
- 2021-09-06 CN CN202180073815.0A patent/CN116615430A/zh active Pending
- 2021-09-06 JP JP2023515088A patent/JP7821785B2/ja active Active
- 2021-09-06 EP EP21863727.0A patent/EP4211133A4/en active Pending
- 2021-09-06 WO PCT/CN2021/116684 patent/WO2022048665A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927214B1 (en) * | 1999-01-15 | 2005-08-09 | Novo Nordisk A/S | Non-peptide GLP-1 agonists |
| CN109790161A (zh) * | 2016-09-26 | 2019-05-21 | 中外制药株式会社 | 具有glp-1受体激动剂作用的吡唑并吡啶衍生物 |
| JP2019099571A (ja) * | 2017-11-29 | 2019-06-24 | 中外製薬株式会社 | Glp−1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025119206A1 (en) * | 2023-12-05 | 2025-06-12 | Fortvita Biologics Inc. | Glp-1 receptor targeting compounds and uses thereof |
| WO2026031819A1 (en) * | 2024-08-06 | 2026-02-12 | Insilico Medicine Ip Limited | Novel compounds as glp-1r agonists and uses thereof |
| WO2026086876A1 (zh) * | 2024-10-23 | 2026-04-30 | 郑州同源康医药有限公司 | 作为glp-1r激动剂的化合物 |
| CN119176808A (zh) * | 2024-11-25 | 2024-12-24 | 山东法恩新材料科技有限公司 | 一种glp-1激动剂及其制备方法和应用 |
| CN119176808B (zh) * | 2024-11-25 | 2025-12-26 | 山东法恩新材料科技有限公司 | 一种glp-1激动剂及其制备方法和应用 |
| WO2026108956A1 (zh) * | 2024-11-25 | 2026-05-28 | 山东法恩新材料科技有限公司 | 一种glp-1激动剂及其制备方法和应用 |
| WO2026145540A1 (zh) * | 2024-12-31 | 2026-07-09 | 正大天晴药业集团股份有限公司 | 含多稠环结构的化合物的结晶及其制备方法 |
| WO2026158226A1 (zh) * | 2025-01-21 | 2026-07-30 | 歌礼制药(中国)有限公司 | 一种glp-1r激动剂的注射剂及其制备方法 |
| WO2026158232A1 (zh) * | 2025-01-21 | 2026-07-30 | 歌礼制药(中国)有限公司 | 一种包含glp-1r激动剂的药物组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4211133A4 (en) | 2024-11-27 |
| JP2023540558A (ja) | 2023-09-25 |
| JP7821785B2 (ja) | 2026-02-27 |
| US20230322771A1 (en) | 2023-10-12 |
| EP4211133A1 (en) | 2023-07-19 |
| WO2022048665A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7821785B2 (ja) | ヘテロ環glp-1アゴニスト | |
| US12595264B2 (en) | Heterocyclic GLP-1 agonists | |
| US11897851B2 (en) | Heterocyclic GLP-1 agonists | |
| EP4490155A1 (en) | Heterocyclic glp-1 agonists | |
| US20240366639A1 (en) | Heterocyclic glp-1 agonists | |
| WO2022078380A1 (en) | Heterocyclic glp-1 agonists | |
| WO2022042691A1 (en) | Heterocyclic glp-1 agonists | |
| EP4476216A1 (en) | Heterocyclic glp-1 agonists | |
| EP4476213A1 (en) | Heterocyclic glp-1 agonists | |
| EP4508047A1 (en) | Heterocyclic glp-1 agonists | |
| WO2025045208A1 (en) | Heteroaryl-heterocycloalkyl-based glp-1 agonists | |
| TW202506102A (zh) | 雜環的glp-1促效劑 | |
| EP4634180A1 (en) | Salts and solid forms of a compound having glp-1 agonist activity | |
| HK40098769A (en) | Heterocyclic glp-1 agonists | |
| HK40119249A (en) | Heterocyclic glp-1 agonists | |
| HK40122544A (en) | Heterocyclic glp-1 agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40098769 Country of ref document: HK |